ADMA Biologics Inc (ADMA)
(Delayed Data from NSDQ)
$2.04 USD
-0.05 (-2.39%)
Updated Mar 8, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value F Growth C Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADMANegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.
ADMANegative Net Change AVIRNegative Net Change CSTLNegative Net Change OCGNNegative Net Change
biotechs
4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.
MRNANegative Net Change LXRXNegative Net Change ADMANegative Net Change AVIRNegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals
Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
ADMANegative Net Change AVIRNegative Net Change ARPOPositive Net Change CSTLNegative Net Change
biotechs
Adma Biologics (ADMA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADMANegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.
ADMANegative Net Change SRNENegative Net Change AVIRNegative Net Change CSTLNegative Net Change
biotechs
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
LXRXNegative Net Change RGENNegative Net Change ADMANegative Net Change IMVTPositive Net Change
biotechs
ADMA Biologics (ADMA) in Focus: Stock Moves 6.6% Higher
by Zacks Equity Research
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
ADMANegative Net Change APTONegative Net Change
biotechs medical
Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 9.52% and 7.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ADMANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
ALNYNegative Net Change VRTXPositive Net Change ADMANegative Net Change CGENNegative Net Change
biotechs
Analysts Estimate Adma Biologics (ADMA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADMANegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
New Strong Sell Stocks for October 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
REPositive Net Change HSTPositive Net Change PSXPPositive Net Change ADMANegative Net Change AMCPositive Net Change
consumer-discretionary insurance medical oil-energy reit
Is the Options Market Predicting a Spike in ADMA Biologics (ADMA) Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
ADMANegative Net Change
medical
ADMA Biologics (ADMA) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
LGNDNegative Net Change ADMANegative Net Change
biotechs
Are Options Traders Betting on a Big Move in ADMA Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
ADMANegative Net Change
Adma Biologics (ADMA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -21.05% and -24.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ADMANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Is the Options Market Predicting a Spike in ADMA Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
ADMANegative Net Change
medical
Are Options Traders Betting on a Big Move in ADMA Biologics (ADMA) Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
ADMANegative Net Change
medical
Adma Biologics (ADMA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ADMANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank